(Q37957961)

25 August 2017

title

Clinical trials of intranasal delivery for treating neurological disorders--a critical review (English)

1 reference

25 August 2017

Xinfeng Liu

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

Expert Opinion on Drug Delivery

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1681-1690

1 reference

Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

The blood-brain barrier: bottleneck in brain drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Improving influence of insulin on cognitive functions in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Filamentous phage as vector-mediated antibody delivery to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal delivery of stem cells to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Nanoparticles and the brain: cause for concern?.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal delivery to the central nervous system: mechanisms and experimental considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Regulation of food intake and body weight by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intracerebroventricular insulin enhances memory in a passive-avoidance task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal insulin improves memory in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Obese men respond to cognitive but not to catabolic brain insulin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Insulin and neurodegenerative disease: shared and specific mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal insulin as a therapeutic option in the treatment of cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

A familial pericentric inversion of chromosome 22 with a recombinant subject illustrating a 'pure' partial monosomy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

The effects of vasopressin on human facial responses related to social communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Neuropeptidergic regulation of affiliative behavior and social bonding in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Prosocial effects of oxytocin and clinical evidence for its therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin increases trust in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin improves "mind-reading" in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin increases gaze to the eye region of human faces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin attenuates amygdala responses to emotional faces regardless of valence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin shapes the neural circuitry of trust and trust adaptation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Selective amnesic effects of oxytocin on human memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Post-learning intranasal oxytocin modulates human memory for facial identity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin Makes a Face in Memory Familiar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin Enhances Amygdala-Dependent, Socially Reinforced Learning and Emotional Empathy in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal oxytocin modulates EEG mu/alpha and beta rhythms during perception of biological motion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Dopamine, oxytocin, and vasopressin receptor binding in the medial prefrontal cortex of monogamous and promiscuous voles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Dose-response relationships of intranasal cholecystokinin and the P300 event-related brain potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Repetitive intranasal administration of cholecystokinin potentiates its central nervous effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Direct access of drugs to the human brain after intranasal drug administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Nasal administration of an angiotensin antagonist in the rat model: effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Nasal drug delivery--possibilities, problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

1,026 experimental treatments in acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Update of the stroke therapy academic industry roundtable preclinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Translational research: understanding the continuum from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

Apolipoprotein E in Alzheimer's disease and other neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.633508

10.1517/17425247.2011.633508

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference